Study finds orforglipron taken orally once daily leads to significant body weight loss
New research presented at the Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria (Sept 15–19) and simultaneously published in NEJM shows that daily treatment with the new once-daily GLP-1 agonist orforglipron results in substantial weight loss in people living with obesity that do not have type 2 diabetes.
Eli Lilly Rolls Out Its GLP-1 Strategy Worldwide
By partnering with telehealth firms and e-commerce platforms, the Mounjaro maker hopes to replicate its US success abroad as it moves into the EU, Asia and Middle East, Lilly’s international president told Reuters.
Medicare should cover GLP-1 obesity drugs
Despite the growing prevalence and impact of obesity in America, it took Medicare over 40 years to cover bariatric surgery, one of the first treatments for the disease. The decades-long delay in providing coverage for bariatric surgery in Medicare meant that an entire generation of Americans died from obesity-related diseases while waiting for access to […]
GLP-1 drugs could save millions of lives — and spark a pension crisis
GLP-1 drugs are so powerful that, in 20 years, they can save millions from premature death, a leading insurance company says.
Lilly’s GLP-1 Pill Outperforms Older Novo Drug
Patients on Eli Lilly & Co.’s experimental diabetes pill lost more weight and had better blood sugar control than those on an older, approved rival from Novo Nordisk in the first head-to-head trial of the two medicines. Madison Muller reports on “Bloomberg Open Interest.”
Weight-loss drug giants face sternest test yet
The weight-loss drug boom has, in many ways, turned into a generational market story. For perspective, the U.S. obesity crisis touches 40% of adults, and weight-loss drug sales could top a whopping $100 billion by 2030 as GLP-1 use expands across diabetes into chronic weight management. At the center of it are Big Pharma plays […]
Eli Lilly’s obesity pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial – CNBC
Eli Lilly’s obesity pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial CNBC Lilly’s oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine Eli Lilly and Company Daily weight loss pill can help cut body weight by a fifth, trial shows The Guardian Lilly’s […]
Eli Lilly posts full trial data for obesity pill (LLY:NYSE) – Seeking Alpha
Eli Lilly posts full trial data for obesity pill (LLY:NYSE) Seeking Alpha Eli Lilly’s obesity pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial CNBC Lilly’s oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine Eli Lilly and Company Daily weight loss pill can […]
Antipsychotic-treated patients with schizophrenia see benefits from semaglutide, study claims
A multicenter collaboration of Danish researchers reports that once-weekly semaglutide for 30 weeks lowered blood sugar levels and body weight and improved physical quality of life in antipsychotic-treated adults with schizophrenia and prediabetes.
Swiss Re Says GLP-1 Drugs Could Reduce US Mortality by Up to 6.4%
Reinsurance company Swiss Re said on Wednesday that widespread use of GLP-1 drugs to treat obesity could reduce the annual rate of death by up to 6.4% in the United States… Reuters Health Information